BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Last trade$7.47
Day change+$0.015 (+0.20%)
Day range$7.34 – $7.56
Volume1,534,947
Market cap$1.92B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.92B
Price / earnings
—
Price / book
-4.82×
Price / sales
1.99×
EV / sales
2.7×
EV / EBITDA
-9.04×
Profitability
Earnings per share
-$1.40
Return on assets
-60.85%
Return on equity
90.51%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-1.95×
Current ratio
2.71×
Quick ratio
2.64×
Cash ratio
0.5×
Cash flow
Price / cash flow
5.22×
Price / free cash flow
5.24×
Free cash flow
$365.85M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for BCRX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$180.29M
$218.25M
$156.41M
$406.56M
$159.4M
$163.35M
$145.53M
$131.53M
Cost of revenue
$1.57M
$3.84M
$5.38M
$9.52M
$2.19M
$2.8M
$4.57M
$6.09M
Gross profit
$178.72M
$214.41M
$151.04M
$397.03M
$157.21M
$160.56M
$140.97M
$125.44M
Selling, general and administrative
$67.18M
$63.98M
$94.55M
$95.78M
$83.01M
$87.38M
$82.47M
$80.51M
Research and development
$58.21M
$51.97M
$758.08M
$40.87M
$44.6M
$43.39M
$37.27M
$49.44M
Total operating expenses
$125.39M
$115.95M
$852.63M
$136.65M
$127.62M
$130.77M
$119.74M
$129.95M
Operating income
$53.33M
$98.47M
-$701.6M
$260.39M
$29.59M
$29.79M
$21.23M
-$4.51M
Interest expense
-$21.19M
-$21.71M
-$19.78M
-$14.14M
-$19.66M
-$21.58M
-$23.49M
-$24.45M
Income before taxes
$38.59M
$79.47M
-$720.81M
$248.02M
$12.13M
$6.49M
$758K
-$25.99M
Income taxes
$669K
$1.08M
$1M
$2.17M
-$769K
$1.4M
$726K
$804K
Net income
$37.92M
$78.4M
-$721.81M
$245.85M
$12.9M
$5.09M
$32K
-$26.8M
Net income attributable to common shareholders
$37.92M
$78.4M
-$721.81M
$245.85M
$12.9M
$5.09M
$32K
-$26.8M
EBITDA
$54.17M
$98.38M
-$700.54M
$260.78M
$29.93M
$30.12M
$21.56M
-$4.2M
Basic earnings per share
$0.15
$0.31
-$2.98
$1.17
$0.06
$0.02
$0.00
-$0.13
Diluted earnings per share
$0.14
$0.30
-$2.98
$1.12
$0.06
$0.02
$0.00
-$0.13
Recent news
Company coverage with links to the original publishers.
Zacks highlights four commercial-stage biotechnology companies demonstrating strong revenue growth and market penetration: TG Therapeutics (Briumvi for MS), BioCryst Pharmaceuticals (Orladeyo for HAE), Insmed (Brinsupri and Arikayce for respiratory diseases), and Madrigal Pharmaceuticals (Rezdiffra for MASH). All four companies show consistent quarterly sales increases, expanding patient adoption, and strategic initiatives to broaden their commercial reach through new formulations, international expansion, and label expansions.
Bioventus (BVS) reported Q3 2026 earnings of $0.17 per share, matching consensus estimates, but revenues of $142.44 million missed expectations by 4.74%. The stock has gained 79.1% year-to-date, significantly outperforming the S&P 500's 10.7% gain. The company received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. BioCryst Pharmaceuticals (BCRX) is expected to report results on November 4 with anticipated earnings of $0.10 per share, representing 66.7% year-over-year growth.
BioCryst Pharmaceuticals (BCRX) has gained 4.9% over the past four weeks and currently trades at $8.52. Wall Street analysts have set a mean price target of $20.27, suggesting a potential upside of 137.9%. The stock holds a Zacks Rank #2 (Buy) rating, supported by positive earnings estimate revisions. However, the article cautions that price targets alone should not be the sole basis for investment decisions, as analysts often set overly optimistic targets due to business incentives.
BioCryst Pharmaceuticals is expected to report Q3 2026 earnings on November 4, with consensus EPS of $0.10 (up 66.7% YoY) and revenues of $166.45 million (up 4.4% YoY). However, the company has a negative Earnings ESP of -30.00% due to recent analyst estimate revisions downward, making it difficult to predict an earnings beat despite its Zacks Rank #2 rating. The company beat estimates significantly in the last quarter (+114.29% surprise).
BioCryst Pharmaceuticals announced FDA approval of ORLADEYO 150 mg oral pellets for adults and adolescents aged 12 and older with hereditary angioedema (HAE). The new pellet formulation provides an alternative to capsules for patients with difficulty swallowing or those who prefer pellet administration. ORLADEYO remains the first and only targeted oral prophylactic therapy for HAE patients aged 2 and above, with clinical data showing 91% attack-rate reduction at 96 weeks.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.